Shopping Cart
- Remove All
Your shopping cart is currently empty
KA2507 is a potent and selective HDAC6 inibitor with an IC50 of 2.5nM.

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $35 | In Stock | |
| 5 mg | $81 | In Stock | |
| 10 mg | $129 | In Stock | |
| 25 mg | $247 | In Stock | |
| 50 mg | $372 | In Stock | |
| 100 mg | $496 | In Stock | |
| 200 mg | $693 | In Stock | |
| 1 mL x 10 mM (in DMSO) | $29 | In Stock |
| Description | KA2507 is a potent and selective HDAC6 inibitor with an IC50 of 2.5nM. |
| Targets&IC50 | HDAC6:2.5nm, HDAC8:621 |
| In vitro | At concentrations selective for HDAC6 inhibition, KA2507 did not inhibit in vitro proliferation of mouse or human cancer cells. |
| In vivo | KA2507 (100-200 mg/kg; p.o.; daily; for 20 days) inhibits tumor growth in the syngeneic B16-F10 mouse melanoma model and shows antitumor efficacy in CT26 and MC38 colorectal cancer models. Tumor sample analysis reveals that at efficacious doses, KA2507 modulates biomarkers of antitumor immunity, resulting in reduced STAT3 activation (measured by phospho-STAT3), decreased PD-L1 expression, and increased MHC class I expression. However, KA2507 exhibits poor oral bioavailability (mice 15%) and Cmax (mice 300 ng/mL) following oral administration (mice 200 mg/kg). [1] |
| Molecular Weight | 322.32 |
| Formula | C16H14N6O2 |
| Cas No. | 1636894-46-6 |
| Smiles | ONC(=O)c1ccc(CN(c2cnccn2)c2cnccn2)cc1 |
| Relative Density. | 1.407 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 60 mg/mL (186.15 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (6.21 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.